Time-independent proportionality between red marrow and plasma activity concentration may be too simplistic. Individualized imaged-based dosimetry is probably required for the optimal therapeutic delivery of radiolabeled antibodies, which does not compromise red marrow and may allow, for some patients, a substantial increase in administered activity and thus tumor dose, based on a study in the April issue in the Journal of Nuclear Medicine.

In the wake of a study published April 17 in the Journal of the American Medical Association (JAMA) which reported an increased incidence of gastrointestinal morbidity among men with prostate cancer treated with proton therapy compared with intensity-modulated radiation therapy (IMRT), proton therapy providers have rallied to dispute the findings and study methodology.

GE Healthcare and NXT2B, a privately owned venture capital company started in 2011, have entered into a joint financing agreement with the goal of developing a micro-scale radiotracer infrastructure including cyclotron and PET tracer production.

While Congress ponders dismantling the Patient Protection and Affordable Care Act, researchers are exploring how its existenceand potentially its absencecould affect healthcare. This week, the act provided a framework for two studies, one looking at the donut hole and another at cherry picking, and both provided food for thought.

An analysis of three different types of radiation therapy used to treat nonmetastatic prostate cancer found intensity-modulated radiation therapy (IMRT) may be associated with improved disease control and fewer adverse effects than conformal radiation therapy and proton therapy, according to results of a study presented at a Journal of the American Medical Association (JAMA) media briefing at the National Press Club and published in the April 17 issue of the JAMA.

GE Healthcare has received FDA clearance of Q.Freeze, a PET/CT quantitative imaging technology designed for treatment evaluation earlier in a patients cancer treatment.

St. Jude Medical has received CE Mark approval of the Ellipse implantable cardioverter-defibrillator (ICD), which is smaller in design.

Phoenix Cardiac Surgery of Phoenix and Prescott, Ariz., has agreed to pay the U.S. Department of Health and Human Services (HHS) a $100,000 settlement and take corrective action to implement policies and procedures to safeguard the protected health information of its patients.